- Home
- CRF vs NEO Comparison
CRF vs NEO Comparison
Compare CRF & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- NEO
- Stock Information
- Founded
- CRF 1973
- NEO 2001
- Country
- CRF United States
- NEO United States
- Employees
- CRF N/A
- NEO N/A
- Industry
- CRF Finance/Investors Services
- NEO Precision Instruments
- Sector
- CRF Finance
- NEO Health Care
- Exchange
- CRF Nasdaq
- NEO Nasdaq
- Market Cap
- CRF 1.2B
- NEO 1.2B
- IPO Year
- CRF N/A
- NEO 1999
- Fundamental
- Price
- CRF $7.95
- NEO $10.08
- Analyst Decision
- CRF
- NEO Buy
- Analyst Count
- CRF 0
- NEO 10
- Target Price
- CRF N/A
- NEO $12.56
- AVG Volume (30 Days)
- CRF 1.1M
- NEO 4.7M
- Earning Date
- CRF 01-01-0001
- NEO 10-28-2025
- Dividend Yield
- CRF 18.10%
- NEO N/A
- EPS Growth
- CRF N/A
- NEO N/A
- EPS
- CRF 1.40
- NEO N/A
- Revenue
- CRF $11,461,786.00
- NEO $709,162,000.00
- Revenue This Year
- CRF N/A
- NEO $10.74
- Revenue Next Year
- CRF N/A
- NEO $9.85
- P/E Ratio
- CRF $5.38
- NEO N/A
- Revenue Growth
- CRF 6.53
- NEO 10.10
- 52 Week Low
- CRF $5.70
- NEO $4.72
- 52 Week High
- CRF $9.56
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- CRF 44.64
- NEO 55.66
- Support Level
- CRF $8.00
- NEO $9.42
- Resistance Level
- CRF $8.10
- NEO $10.75
- Average True Range (ATR)
- CRF 0.08
- NEO 0.57
- MACD
- CRF -0.01
- NEO -0.07
- Stochastic Oscillator
- CRF 36.00
- NEO 33.40
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.